Autologous CD19 chimeric-antigen receptor (CAR) T cells demonstrated remarkable remission rates in relapsed and refractory acute lymphoblastic leukemia (R/R ALL). Here, we report results from a phase 1b/2 study of in-house produced CD19 CAR with a CD28 costimulatory domain.
| BACKGROUND
Acute lymphoblastic leukemia (ALL) is a disease of the bone marrow and hematopoietic tissue. Nevertheless, extramedullary (EM) relapse is well described in ALL, with specific sanctuary sites such as the testes and central nervous system (CNS) being less susceptible to systemic chemotherapy, requiring radiation or intrathecal therapy. 1, 2 Although isolated EM first relapse of ALL usually has a better outcome, 1,2 prognosis of multiple relapsed ALL is poor. 3, 4 Recent advances with adoptive immunotherapy using autologous
T cells transduced with a chimeric-antigen receptor (CAR) targeting
CD19 resulted in high rates of clinical remissions of relapsed and refractory (R/R) ALL in multiple studies. [5] [6] [7] [8] [9] [10] [11] [12] Despite differences in CAR design, similar remission rates and toxicity profiles are seen across these trials. Toxicities occur mostly as a result of the hyperactivation of the immune system, leading to cytokine release syndrome (CRS). Severe CRS is related to the CAR T cell dose and to disease burden, with less toxicity reported in patients with low disease burden. 5, 6, 13 Durability of CAR T-cell persistence is affected by the CAR design. CAR constructs containing 41BB have shown increased persistence and a tendency toward central-memory phenotype compared with CD28-based CARs, 14 but these have not been tested head-to-head with regards to clinical outcome in patients.
EM involvement has not been the focus of any clinical reports of CAR T cells, and has disqualified participation in some. 5, 10 In contrast to hematologic malignancies, within solid tumors the stromal and Michal J. Besser and Amos Toren contributed equally to this work.
inflammatory microenvironment suppresses immune activation. 15 Moreover, EM relapses have been reported after blinatumomab, a CD19-CD3 bispecific engager with a similar mechanism of action to CAR T cells. 16 Here we report our experience using locally produced CD19 CAR T cells following a fludarabine and cyclophosphamide lymphodepleting regimen, in children and young adults with R/R ALL. We included patients with either bone marrow relapse or EM disease, including CNS involvement. To reduce potential toxicity, we attempted leukemic debulking with 2 chemotherapy combinations prior to the lymphodepleting regimen and CAR T cell administration. All responding patients were referred to allogeneic HSCT, regardless of their prior HSCT status.
2 | METHODS
| Study design
The study was designed as a phase 1b/2 trial approved by the Sheba Patients with high disease burden, defined as >20% blasts in the bone marrow, were offered an additional course of chemotherapy prior to the lymphodepleting regimen preceding CAR T-cell infusion.
Patients received either FLAG (fludarabine, high-dose ARA-C, and G-CSF) or BVDAsp (bortezomib, vincristine, dexamethasone, and asparginase 17 ) regimens, according to the treating physician discretion. Disease assessment was repeated following chemotherapy course. Since fludarabine is associated with prolonged T-cell depletion, leukapheresis was performed prior to FLAG chemotherapy, and cells were cryopreserved prior to CAR-T production. In all other patients fresh apheresis products were used for CAR T cell production.
| Cellular production and administration
Patients underwent a single leukapheresis procedure; peripheral blood mononuclear cells (PBMC) were isolated, activated and transduced with a gammaretrovirus encoding for a CD19 CAR (based on an 
| Patient evaluation
Primary endpoints of the study were production feasibility, patient safety and best overall response rates, documented 28 days after infusion. Production feasibility was defined as ability to achieve target cel- 
| Statistical analysis
We report the intent-to-treat analysis, including patients receiving Table 1 .
In total 14 patients were referred to the study with high disease burden, and were offered a chemotherapy course prior to the conditioning and cell therapy: 12 for high-burden marrow involvement and 2 for isolated EM disease. Eight patients received BVDAsp course, 5 received FLAG combination and 1 patient declined treatment. Disease reduction was achieved in 11 of 13 patients (84%), with no one achieving MRD negative status (Supporting Information Table S1 ) and all evaluable for CAR T cell efficacy. All patients recovered from toxicities of prior regimens except 1 with infectious complications following FLAG chemotherapy with active refractory disease. Seven additional patients were referred to CAR T cells with low-burden disease.
| CAR T-cell production
The median CD3 count prior to apheresis was 975/μL blood (range, 131-2200, Figure 1A ). Despite an initial requirement of CD3 count above 250/μL per protocol, 2 patients with rapidly progressive disease underwent apheresis with a CD3 count of 131 and 165 per microliter, both achieving the target cellular dose of 1 × 10 6 CAR T cells per kg ( Figure 1A ). Following apheresis and ficol, the median CD3+ percentage in the starting material was 57% (range, 7%-86%), and the median CD19+ percentage was 4.3% (range, 0%-53%, Figure 1B ). Cell production was started from cryopreserved cells in 5 cases and from fresh apheresis in 16. Production feasibility was achieved in 95% (20/21) of apheresis products, with only 1 production failure. All patients received a fresh CAR-T product, with a production time of 9-10 days.-fold expansion was 28.7 AE 23.4 (range 1.5-95.2), and median transduction efficacy achieved was 77% (range, 18-93%, Figure 1C ). The product included both CD4+ (32.9% AE 16%) and CD8+ T cells (61.3% AE 19.2%) and did not contain any CD19+ B cells.
| Clinical course and toxicity

Expansion of CAR T cells measured by RT-PCR was noted in 18 of
20 patients infused. Peak CAR expansion was on day 7 in the majority of patients (Figure 2A ), accompanied by peak in fever and elevated Creactive protein (CRP). The median time of detectable CAR by qPCR in the peripheral blood was 23 days, and there was no difference in 
| DISCUSSION
In this phase 1b/2 study of locally produced CD19 CAR T cells, we report a production feasibility of 95% and overall response rate of 90% in patients with R/R ALL, including a unique subset with EM disease.
Safety is a major concern of therapies in ALL, including immunotherapies. In an effort to reduce CRS, patients were offered a chemotherapy course prior to lymphodepletion and CAR T cell infusion. Of 14 patients with high burden leukemia, disease burden reduction was achieved in 11 patients with standard chemotherapy regimens. Two combinations were used: The 4-drug BVDAsp regimen, based on a recent TACL study 17 was safe, and led to significant decrease in blast count without significant compromise of T collection feasibility. Since fludarabine is associated with significant T cell depletion, PBMCs from patients who were referred to FLAG induction were collected prior to chemotherapy, with T cell production starting from thawed cells. The result of this approach -achievement of low disease burden prior to CAR T cells-may have contributed to the overall low grade of CRS observed, with grade 3 CRS seen in only 2 patients (10%), less than that reported by other groups (23%-45% of grades 3-4 CRS). 5, 6, 8, 10 In contrary, neurotoxicity was seen in 11 of 20 patients (55%), similar to the reported rates in other studies (28%-53%). 6, 8, 10, 11, 19 The high rate of neurotoxicity we observed was not related to disease burden, and may be the results of other mechanisms than high cytokine levels due to effector-target interactions. 19 Recently, low disease burden prior to CAR-T cells was reported to be associated with prolonged eventfree survival, 11 suggesting these as key factors in CD28-based CAR T cell therapy. Here, we present several options to reduce disease burden prior to CAR T cells, without affecting the feasibility of CAR T cell production, and with a possible effect not only on safety but on overall outcome.
With regulatory approval of blinatumomab and its off-the-shelf availability, 20 a more complex individualized cellular production for CAR T cells has to demonstrate benefit. Our data demonstrates that patients who failed previous courses of blinatumomab may still respond to CAR T cells, since a majority of patients failing blinatumomab still express CD19. 21 Moreover, we identified a unique pattern of EM ALL resistant to blinatumomab, which may be under-reported. 16 All EM lesions resolved following cellular therapy.
Whether CAR T cells can serve as a definitive anti-leukemia ther-
apy has yet to be concluded, and may depend on CAR persistence, depth of remission achieved, and the potential for CD19 expression loss on leukemic cells. 22, 23 Comparing remission results between different trials is complex, and a randomized clinical trial in R/R ALL has not been performed to date. The CAR in this study includes a CD28 costimulatory domain, associated with early and effective activity, but relatively limited persistence in preclinical studies 14 and clinical reports in ALL. this is masked by the fact that most patients had been transplanted after CAR T therapy. In a study with CD19 CAR T cells for adult ALL, a significant discrepancy was reported between flow-based MRD negative CR (86%) to molecular-based MRD-negativity (59%). 9 Thus, a PCR-negative MRD status following CAR T cells may represent an overall deeper remission. 
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